Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin.

作者信息

Vaynblat Mikhail, Shah Himansu R, Bhaskaran Dinesh, Ramdev Geeta, Davis Wellington J, Cunningham Joseph N, Chiavarelli Mario

机构信息

Division of Cardiovascular Surgery, Department of Surgery, Maimomides Medical Center, Administration Building, Rm D, Department of Surgery, 4802 10th Ave, Brooklyn, NY 11219, USA.

出版信息

Eur J Heart Fail. 2002 Oct;4(5):583-6. doi: 10.1016/s1388-9842(02)00091-0.

DOI:10.1016/s1388-9842(02)00091-0

PMID:12413500

Abstract

AIMS

The purpose of this study was to determine that the administration of an angiotensin converting enzyme (ACE) inhibitor enalapril would confer protection against doxorubicin-induced experimental heart failure, and attenuate the development of left ventricular dysfunction.

METHODS

Seventeen dogs were chronically instrumented with an intracoronary catheter and received doxorubicin weekly for 4 weeks. Animals were assigned to two groups: group 1: untreated heart failure; and group 2: simultaneous enalapril administration (5 mg twice a week). Hemodynamic data were obtained at week 0 and 12. Echocardiography was performed weekly.

RESULTS

Survival improved with simultaneous enalapril administration (36% in group 1 vs. 100% in group 2, P=0.04). The increase in the left ventricular end-diastolic pressure was significantly reduced at week 12 (17+/-1 mmHg in group 1 vs. 9+/-1 mmHg in group 2, P=0.0042). The fall in left ventricular stroke work index was significantly prevented (52% in group 1 vs. 21% in group 2, P=0.006). The increase in right ventricular end-diastolic diameter was significantly reduced by enalapril prophylaxis.